Prospera Financial Services Inc Has $226,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Prospera Financial Services Inc trimmed its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating) by 8.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,595 shares of the biotechnology company’s stock after selling 1,892 shares during the period. Prospera Financial Services Inc’s holdings in Ironwood Pharmaceuticals were worth $226,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. BlackRock Inc. grew its stake in Ironwood Pharmaceuticals by 1.2% during the first quarter. BlackRock Inc. now owns 14,536,759 shares of the biotechnology company’s stock worth $182,873,000 after buying an additional 167,869 shares in the last quarter. State Street Corp boosted its stake in shares of Ironwood Pharmaceuticals by 5.3% in the 1st quarter. State Street Corp now owns 8,297,067 shares of the biotechnology company’s stock valued at $104,377,000 after purchasing an additional 418,756 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Ironwood Pharmaceuticals by 16.6% in the 1st quarter. Renaissance Technologies LLC now owns 3,123,053 shares of the biotechnology company’s stock valued at $39,288,000 after purchasing an additional 443,800 shares in the last quarter. Jupiter Asset Management Ltd. boosted its stake in shares of Ironwood Pharmaceuticals by 9.1% in the 1st quarter. Jupiter Asset Management Ltd. now owns 1,876,727 shares of the biotechnology company’s stock valued at $23,609,000 after purchasing an additional 155,771 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Ironwood Pharmaceuticals by 0.5% in the 1st quarter. New York State Common Retirement Fund now owns 1,821,456 shares of the biotechnology company’s stock valued at $22,914,000 after purchasing an additional 9,150 shares in the last quarter.

Ironwood Pharmaceuticals Stock Down 0.9 %

NASDAQ:IRWD opened at $11.50 on Friday. The firm’s 50 day simple moving average is $10.68 and its 200 day simple moving average is $11.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 25.78 and a quick ratio of 25.78. Ironwood Pharmaceuticals, Inc. has a one year low of $9.73 and a one year high of $12.95. The company has a market cap of $1.76 billion, a PE ratio of 12.11 and a beta of 0.99.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 18,899 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $10.41, for a total transaction of $196,738.59. Following the completion of the transaction, the chief executive officer now owns 712,440 shares in the company, valued at approximately $7,416,500.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 13.10% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IRWD. Capital One Financial began coverage on shares of Ironwood Pharmaceuticals in a research note on Friday, September 2nd. They issued an “overweight” rating and a $15.00 price target on the stock. Wells Fargo & Company raised their price target on shares of Ironwood Pharmaceuticals from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 16th. Finally, StockNews.com assumed coverage on shares of Ironwood Pharmaceuticals in a research report on Wednesday, October 12th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Ironwood Pharmaceuticals Profile

(Get Rating)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.

Featured Stories

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Rating).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.